Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04545970
Other study ID # ASIRC-RS-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 23, 2019
Est. completion date July 6, 2020

Study information

Verified date September 2020
Source Revision Skincare
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized, double-blind, placebo-controlled clinical trial was conducted to assess the efficacy and safety of an anti-aging serum to improve the appearance of expression lines as well as overall skin health of aging skin after 12 weeks of twice-daily use in female subjects, aged 35-60, compared to placebo. A total of 55 subjects completed study participation which included 33 subjects in the active group and 22 subjects in the placebo group.


Description:

This randomized, double-blind, placebo-controlled clinical trial is being conducted to assess the efficacy and safety of the anti-aging serum when used over the course of 12 weeks by women with mild to moderate fine lines, wrinkles and overall photodamage on the global face.

Efficacy and tolerability will be assess through clinical grading at baseline, weeks 4, 8, and 12. Efficacy evaluation on fine lines and wrinkles through clinical grading will also be performed at 15 minutes post product application. Self-assessment questionnaires and VISIA photography will be completed at baseline, weeks 4, 8, and 12. 3D PRIMOS photography will be performed at baseline, weeks 8 and 12.

A total of 55 subjects completed study participation which included 33 subjects in the active group and 22 subjects in the placebo group.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date July 6, 2020
Est. primary completion date March 11, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 35 Years to 60 Years
Eligibility Inclusion Criteria:

- Women between the ages of 35 and 60 years were scheduled for eligibility screening at the study site.

- Women with Fitzpatrick Skin Type I-VI

- Subjects must have mild to moderate global face wrinkles and fine lines

- Subjects may have mild to moderate photo-aging secondary to physiologic aging

- Subjects must have no known medical conditions that, in the investigator's opinion, may interfere with study participation.

- Subjects must be willing to provide verbal understanding and written informed consent.

Exclusion Criteria:

- Female subjects who are pregnant, breast feeding, or planning a pregnancy.

- Subjects with severe overall photo damage as determined by the Investigator.

- Subjects who have any dermatological disorder, which in the investigator's opinion, may interfere with the accurate evaluation of the subject's skin, including rosacea, acne, and excessively oily or dry skin.

- Subjects who have demonstrated a previous hypersensitivity reaction to any of the ingredients of the study products.

- Subjects use of any medications that are known to potentially cause changes in the facial skin as determined by the Investigator.

- Subjects who spend excessive time out in the sun.

- Subjects who are unwilling or unable to comply with the requirements of the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Facial cleanser
Facial cleanser to be used by study participants
Facial moisturizer
Bland moisturizer to be used by study participants after serum in the evening.
Sunscreen
Sunscreen to be applied after application of serum in the morning.

Locations

Country Name City State
United States Ablon Skin Institute Research Center Manhattan Beach California

Sponsors (2)

Lead Sponsor Collaborator
Revision Skincare Ablon Skin Institute Research Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Efficacy Graded by Griffiths' Scale The primary efficacy endpoint will be the Investigator Clinical Grading using Modified Griffith's 10-point Scale. A decrease in scores at Day 28, Day 56 and Day 84 in comparison to baseline indicates an improvement for the indicated parameter.The efficacy parameters will be assessed globally on each subject's face using a modified Griffiths' 10-point scale according to the following numerical definitions (half-point scores may be used as necessary to more accurately describe the skin condition):
0 = none (best possible condition); 1 to 3 = mild; 4 to 6 = moderate;7 to 9 = severe (worst possible condition). The lower the score equates to the best possible outcome.
12 weeks
Primary Objective Tolerability: scores The primary tolerability endpoint will be the Investigator Tolerability Assessment of Erythema, Edema and Dryness. A decrease in scores or lack of significant increase at Day 28, Day 56 and Day 84 in comparison to Baseline indicates tolerability/safety of the test material. Four point scale with a lower score indicating a better outcome.
Example for Erythema:Erythema 0 = None No erythema of the treatment area
= Mild Slight, but definite redness of the treatment area
= Moderate Definite redness of the treatment area
= Severe Marked redness of the treatment area
12 weeks
Secondary Subjective Tolerability: scores The secondary tolerability endpoint will be the Subject Tolerability Assessment of Burning, Itching and Stinging. A decrease in scores or lack of significant increase at Day 28, Day 56 and Day 84 in comparison to Baseline indicates tolerability/safety of the test material. Four point scale with a lower score indicating a better outcome.
Example Burning. 0 = None No burning of the treatment area
= Mild Slight burning sensation of the treatment area; not really bothersome
= Moderate Definite warm, burning of the treatment area that is somewhat bothersome.
= Severe Hot burning sensation of the treatment area that causes definite discomfort and may interrupt daily activities and/or sleep
12 weeks
Secondary Self Assessment Questions The secondary efficacy endpoints will be the Self-Assessment Questionnaire and the Subject Treatment Satisfaction and Ease of Use Questionnaire. A decrease or increase in response values at Day 28, Day 56 and Day 84 indicates an improvement compared to baseline response values. Subjects are asked to rate based on a scoring system of the following: from 5 (completely agree) to 1 (completely disagree). The best outcome is to Completely Agree with the statement/ question being asked. 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT01984619 - Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles N/A
Completed NCT01713985 - Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck N/A
Recruiting NCT01586819 - Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A Phase 3
Completed NCT05254210 - Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device N/A
Completed NCT02604641 - Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin N/A
Completed NCT01519934 - A Retrospective Study to Evaluate the Effectiveness of the Ulthera System N/A
Completed NCT01460927 - TriActive+ Radiofrequency (RF) for Non-invasive Treatment of Wrinkles & Rhytides N/A
Completed NCT03811756 - The Effect of 12-week Dietary Intake of Syrup Containing CoQ10 and Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT04988412 - The Effect of 12-week Dietary Intake of Food Supplements Containing Collagen on Dermis Density and Other Skin Parameters N/A
Completed NCT02913547 - Silk'n HST for Wrinkle Reduction - Clinical Study Protocol N/A
Active, not recruiting NCT02019004 - A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles N/A
Completed NCT02340078 - A Clinical Study to Evaluate the Efficacy and Safety of YVOIRE Volume Plus Versus YVOIRE Volume in Nasolabial Fold Injection N/A
Completed NCT01283464 - Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles Phase 2
Completed NCT01034956 - Outcomes and Patient Experience After Soft Tissue Dermal Filler Injections N/A
Completed NCT02425943 - Sculptra Aesthetic Post-Approval Study Phase 4
Recruiting NCT05847530 - Pilot Evaluation of the Cynosure Potenza™ System for Treatment of Cosmetic Dermatologic Skin Conditions N/A
Enrolling by invitation NCT01847066 - Epidermal Delivery of Ani-Aging Ingredients N/A
Completed NCT01859611 - TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides N/A
Completed NCT01297634 - Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle Phase 4
Completed NCT05011461 - The Effect of Topical Almond Oil vs. Topical Retinol on The Appearance of Facial Wrinkles N/A